MPTP NEUROTOXICITY SYNDROME
\ˌɛmpˌiːtˌiːpˈiː njˌuːɹə͡ʊtəksˈɪsɪti sˈɪndɹə͡ʊm], \ˌɛmpˌiːtˌiːpˈiː njˌuːɹəʊtəksˈɪsɪti sˈɪndɹəʊm], \ˌɛ_m_p_ˌiː_t_ˌiː_p_ˈiː n_j_ˌuː_ɹ_əʊ_t_ə_k_s_ˈɪ_s_ɪ_t_i s_ˈɪ_n_d_ɹ_əʊ_m]\
Sort: Oldest first
-
A condition caused by the neurotoxin 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. MPTP causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36 (2):250-8)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.